全文获取类型
收费全文 | 1259529篇 |
免费 | 98098篇 |
国内免费 | 8838篇 |
专业分类
耳鼻咽喉 | 18125篇 |
儿科学 | 32646篇 |
妇产科学 | 34529篇 |
基础医学 | 177579篇 |
口腔科学 | 37334篇 |
临床医学 | 110146篇 |
内科学 | 243261篇 |
皮肤病学 | 25143篇 |
神经病学 | 97728篇 |
特种医学 | 49819篇 |
外国民族医学 | 287篇 |
外科学 | 196852篇 |
综合类 | 43742篇 |
现状与发展 | 18篇 |
一般理论 | 318篇 |
预防医学 | 86693篇 |
眼科学 | 30896篇 |
药学 | 98814篇 |
55篇 | |
中国医学 | 6724篇 |
肿瘤学 | 75756篇 |
出版年
2021年 | 10588篇 |
2018年 | 13259篇 |
2017年 | 10533篇 |
2016年 | 11298篇 |
2015年 | 13946篇 |
2014年 | 19359篇 |
2013年 | 26003篇 |
2012年 | 35904篇 |
2011年 | 37641篇 |
2010年 | 22488篇 |
2009年 | 20498篇 |
2008年 | 33651篇 |
2007年 | 36502篇 |
2006年 | 36317篇 |
2005年 | 35346篇 |
2004年 | 33338篇 |
2003年 | 32206篇 |
2002年 | 30711篇 |
2001年 | 61427篇 |
2000年 | 62925篇 |
1999年 | 53172篇 |
1998年 | 14750篇 |
1997年 | 13211篇 |
1996年 | 12548篇 |
1995年 | 11757篇 |
1994年 | 11062篇 |
1992年 | 41620篇 |
1991年 | 39981篇 |
1990年 | 38897篇 |
1989年 | 37813篇 |
1988年 | 35001篇 |
1987年 | 34194篇 |
1986年 | 32155篇 |
1985年 | 30817篇 |
1984年 | 22855篇 |
1983年 | 19301篇 |
1982年 | 11381篇 |
1981年 | 10252篇 |
1979年 | 21906篇 |
1978年 | 15257篇 |
1977年 | 12982篇 |
1976年 | 11451篇 |
1975年 | 12632篇 |
1974年 | 15516篇 |
1973年 | 14823篇 |
1972年 | 14215篇 |
1971年 | 13335篇 |
1970年 | 12621篇 |
1969年 | 12345篇 |
1968年 | 11038篇 |
排序方式: 共有10000条查询结果,搜索用时 390 毫秒
91.
92.
目的观察25-羟维生素D3(Vit D3)对2型糖尿病(T2DM)患者早期肾损害的临床疗效。方法纳入T2DM早期肾损伤患者80例,采用随机数字表法等分为治疗组与对照组,对照组继续原有降糖方案,治疗组在既往用药基础上,肌肉注射Vit D3注射液,疗程均为10个月,治疗结束后进行疗效评价。结果 1与治疗前相比,治疗组糖化血红蛋白(HbA1c)、总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平上调,微量白蛋白(MA)、β2-微球蛋白(β2-M)及肾脏损伤分子-1(KIM-1)水平下调,治疗组低于对照组差异有统计学意义(P<0.05)。2与治疗前相比,治疗组治疗后Vit D3水平上调,治疗组高于对照组差异有统计学意义(P<0.01)。3T2DM患者Vit D3水平与MA(r=-0.432),β2-M(r=-0.615),及KIM-1(r=-0.763)水平均呈负相关(P<0.05)。结论 Vit D3可有效减轻T2DM患者的早期肾损害,对肾脏具有保护作用。 相似文献
93.
94.
95.
96.
97.
Mariano E. Menendez Suleiman Y. Sudah Patrick J. Denard 《Seminars in Arthroplasty》2022,32(3):644-649
BackgroundThe growing enthusiasm for the use of reverse shoulder arthroplasty (RSA) in the treatment of primary glenohumeral osteoarthritis (GHOA) with an intact rotator cuff is based on data derived from single-center studies with limited generalizability and follow-up. This study compared patient-reported outcomes (PROs) between RSA and total shoulder arthroplasty (TSA) for the treatment of primary GHOA with up to 5-year follow-up and examined temporal trends in the treatment of GHOA between 2012 and 2021.MethodsA retrospective review was performed on patients with primary GHOA undergoing primary arthroplasty surgery from the Surgical Outcomes System global registry between 2012 and 2021. PROs including the American Shoulder and Elbow Surgeons (ASES) score, Single Assessment Numeric Evaluation (SANE) score, and visual analog scale (VAS) for pain were compared between RSA and TSA at 1, 2, and 5 years postoperatively.ResultsA total of 4451 patients were included, with 2693 (60.5%) undergoing TSA and 1758 (39.5%) undergoing RSA. Both RSA and TSA provided clinically excellent outcomes at 1 year postoperatively (ASES: 80.8 ± 17.9 vs. 85.9 ± 15.2, respectively; SANE: 74.8 ± 24.7 vs. 79.5 ± 22.9; VAS pain: 1.3 ± 2.0 vs. 1.1 ± 1.7; all P < .05) that were maintained at 2 years (ASES: 81.3 ± 19.3 vs. 87.3 ± 14.9; SANE: 74.8 ± 26.2 vs. 79.7 ± 24.7; VAS pain: 1.3 ± 2.1 vs. 1.0 ± 1.6; all P < .05) and 5 years (ASES: 81.7 ± 16.5 vs. 86.9 ± 15.3; SANE: 71.6 ± 28.5 vs. 78.2 ± 25.9; VAS pain: 1.0 ± 1.7 vs. 1.0 ± 1.7; all P < .05), with statistical significance favoring TSA. After controlling for age and sex, there was an adjusted difference of 4.5 units in the ASES score favoring TSA (P = .005) at 5 years postoperatively but no differences in adjusted SANE (P = .745) and VAS pain (P = .332) scores. The use of RSA for GHOA grew considerably over time, from representing only 17% of all replacements performed for GHOA in 2012 to nearly half (47%) in 2021 (P < .001).ConclusionRSA as a treatment for GHOA with an intact rotator cuff seems to yield PROs that are largely clinically equivalent to TSA extending to 5 years postoperatively. The observed statistical significance favoring TSA appears to be of marginal clinical benefit based on established minimal clinically important differences and may be a result of the large sample size. Further research using more granular clinical data and examining differences in range of motion and complications is warranted as it may change the value analysis. 相似文献
98.
T.-Y. Huang Y.-J. Hsia M.-Y. Sung Y.-T. Wu P.-C. Hsu 《International journal of oral and maxillofacial surgery》2021,50(8):1100-1106
Zygomatic implant treatment is widely applied for severe maxillary atrophy to help rehabilitate the maxillary dentition. This retrospective study was performed to evaluate the actual radiographic bone–implant contact (rBIC) lengths of zygomatic implants. The records of 28 patients who underwent zygomatic implant surgery and subsequent follow-up examinations between August 2013 and September 2018 in the Department of Oral and Maxillofacial Surgery, Taipei Tzu Chi Hospital were reviewed. The surgeries were performed by a single surgeon using the same treatment protocol. All patients had a computed tomography scan at 1 year after the surgery. Using three-dimensional imaging software, an investigator measured the rBIC lengths of 66 implants and documented their clinical status. The implant survival rate was 100%. The mean rBIC length was significantly longer in male patients than in female patients (20.80 ± 5.88 mm versus 17.79 ± 6.34 mm; P = 0.028). The mean rBIC length of double zygomatic implants was significantly longer when compared to that of single implants (21.11 ± 6.23 mm versus 17.75 ± 5.85 mm; P = 0.027). This article is novel in reporting the exact rBIC lengths of zygomatic implants in a clinical setting. The results showed that zygomatic implants are a viable treatment modality for full-mouth rehabilitation. 相似文献
99.
100.